UCLA

UCLA enters the account of psychedelic research through psychiatrist Charles Grob and his work on psilocybin for cancer anxiety. His 2011 pilot study helped clear a path for later studies at New York University and Johns Hopkins University, linking the institution to the renewed clinical investigation of psychedelic therapy. The account gives no broader institutional history or description of UCLA’s research structure; its documented significance is specific, but consequential: work associated with Grob helped reconnect contemporary clinical research to a line of inquiry interrupted by cultural and regulatory pressure.

Grob and the Research Revival

Grob is described as a UCLA psychiatrist who played an important role in the revival of psychedelic research. His 2011 pilot study addressed psilocybin for cancer anxiety and preceded the larger, related trials at New York University and Johns Hopkins University. In this sequence, the pilot was not presented as a final demonstration of efficacy. It was a step that helped make subsequent research possible, reopening a question that had been set aside when sanctioned psychedelic therapy ended in the 1970s.

Grob characterized the newer work as, in many ways, picking up the torch from earlier researchers forced to stop under cultural pressure. That continuity matters to UCLA’s place in this account: its connection is not to an untouched new field, but to the recovery and renewed testing of older clinical questions. The past supplied precedents and accumulated claims; contemporary researchers still had to revisit them according to current scientific standards before psychedelic therapy could seek acceptance in modern medicine.

Therapy at the Border of Medicine and Spirituality

Grob’s account of psychedelic therapy also makes clear why its revival was more than a matter of restarting drug trials. The treatment model described in the book depends on the experience elicited by a high dose and on the circumstances in which it occurs. In an earlier formulation of the field, Grob called psychedelic therapy a form of "applied mysticism." The phrase names a difficulty for institutions such as UCLA: the treatment’s proposed therapeutic action is entangled with experiences commonly described as spiritual, while psychiatric medicine increasingly favors a biochemical account of the mind.

The surrounding debate set psychedelic therapy apart from approaches more readily accommodated by established psychiatry. Psychotomimetic theories treated drug effects as resembling familiar forms of mental illness; psycholytic treatment could be incorporated as an adjunct to psychoanalysis. The psychedelic model instead proposed a single high-dose session intended to bring about a conversion-like experience, requiring a reimagining of the roles of patient and therapist. Grob’s description of this model as applied mysticism marks the point where therapeutic practice crosses conventional boundaries between religion and science, sickness and health, and healer and sufferer.

Methods and the Problem of Evidence

The research questions associated with Grob’s work also expose practical limits in standard drug-trial methods. Participants and guides may recognize whether psilocybin or a placebo has been administered, making conventional blinding difficult. Researchers must also consider how to distinguish a drug’s effects from the influence of expectation, the therapeutic relationship, and the treatment environment. These factors complicate attempts to isolate a single cause, particularly when the treatment is understood to work partly by occasioning a particular kind of experience.

Grob argued that strict scientific methodology alone might not be sufficient to evaluate hallucinogens’ therapeutic potential. He urged researchers to consider the shamanic paradigm, in which the therapist deliberately attends to what the book calls "the critical extra-pharmacological variables" and uses the medicines’ heightened suggestibility within a carefully shaped context. This position does not remove the need for rigorous study; it identifies the difficulty of applying methods designed to isolate a drug from the circumstances of its use when those circumstances may be part of the treatment itself.

Institutional Significance and Limits

At a later discussion of psychedelic psychiatry, Grob’s formulation of the problem met a complementary concern from leaders in mental-health institutions. Tom Insel, then former head of the National Institute of Mental Health, praised the model’s emphasis on psychedelic-assisted psychotherapy while warning that regulators accustomed to evaluating drugs in isolation might struggle with it. He also cautioned that safety, rigor, and reputational risks could not be neglected. The exchange presented institutional recognition not as automatic acceptance, but as a threshold the field would have to cross carefully.

UCLA’s documented significance in this account is therefore concentrated in Grob’s role: his pilot study helped enable later clinical work, while his public defense of psychedelic therapy articulated the methodological and conceptual challenge that the research revival faced. The account does not establish that every debate or later trial described took place at UCLA, nor does it portray the university as the sole center of the revival. It places UCLA within a wider research network, where the effort to test therapeutic promise had to contend with the very features—experience, expectation, context, and spiritual interpretation—that made these treatments difficult to fit into conventional medical frameworks.